Please assess the completion status of the following clinical trial:

Trial Title: Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be at least 18 years of age and in good general health as confirmed by a medical history.~* Females of childbearing potential must have a negative urine pregnancy test on Day 1 and must agree to use adequate birth control methods during the entire study.~* A clear diagnosis of plaque psoriasis must have been previously established and the disease must have been present at least 6 months.~* Subjects must have lesions suitable for evaluating response to test agents. The severity of the disease at Day 1 must be rated at least 2 (Mild) for each of the key psoriasis characteristics (scaling, erythema, and plaque elevation).~* Subjects must be able to understand the requirements of the study, abide by the restrictions, and return for the required examinations. All subject must sign the statement of informed consent approved for the study.~Exclusion Criteria:~* Subjects who are pregnant (determined from a urine pregnancy test on Day 1).~* Subjects who are nursing.~* Subjects with known hypersensitivity to any components of the test medication.~* Subjects requiring any other medication (topical or systemic) that may affect the course of the disease during the study period (e.g. antibiotics, sedating antihistamines).~* Subjects using biologics or any other systemic treatment for psoriasis within 12 weeks of entering the study.~* Subjects using systemic corticosteroids within 28 days of entering the study; subjects using topical corticosteroids or other topical therapies (other than emollients) at any location on the body within 1 week of entering the study.~* Subjects with overt pre-existing telangiectasia or skin atrophy at intended treatment sites.~* Subjects who are using any medication or has any disease which in the judgment of the investigator will interfere with the conduct or interpretation of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only
- 2 (Type: PLACEBO_COMPARATOR): Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only

Based on this trial design, predict the completion outcome and termination type (if applicable).